Jiaxin Cao

Jiaxin Cao

Auto-generated profile, based on publicly available information

Jiaxin Cao

Department of Anesthesiology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangzhou China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YMYuxiang Ma
Yuxiang Ma
JCJiaxin Cao
Jiaxin Cao
YZYang Zhang
Yang Zhang
QLQianwen Liu
Qianwen Liu
WFWenfeng Fang
Wenfeng Fang
LZLi Zhang
Li Zhang

30 March 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JCJiaxin Cao
Jiaxin Cao
KZKangmei Zeng
Kangmei Zeng
QCQun Chen
Qun Chen
TYTing Yang
Ting Yang
FLFeiteng Lu
Feiteng Lu
HZHongyun Zhao
Hongyun Zhao
End-stage nasopharyngeal carcinoma (NPC) has unsatisfactory survival. The limited benefit of chemotherapy and the scarcity of targeted drugs are major challenges in NPC. New approaches to treat late-stage NPC are urgently required. In this study, we explored whether the dual PI3K/mTOR inhibitor, PQR309, exerted a favorable antineoplastic effect and sensitized the response to gemcitabine in NPC. We observed that PI3K expression was positive and elevated in 14 NPC cell lines compared with that in normal nasopharygeal cell lines. Patients with NPC with higher PI3K levels displayed poorer prognosis. We subsequently showed that PQR309 alone effectively decreased the viability, invasiveness, and migratory capability of NPC cells and neoplasm development in mice xenograft models, and dose-dependently induced apoptosis. More importantly, PQR309 remarkably strengthened the anti-NPC function of gemcitabine both in vivo and in vitro. Mechanistically, PQR309 sensitized NPC to gemcitabine by increasing caspase pathway-dependent apoptosis, blocking GSK-3β and STAT3/HSP60 signaling, and ablating epithelial-mesenchyme transition. Thus, targeting PI3K/mTOR using PQR309 might represent a treatment option to promote the response to gemcitabine in NPC, and provides a theoretical foundation for the study of targeted drugs combined with chemotherapy for NPC.

2 June 2024 in Medcomm
Verified
Journal Article
Open access
ZZZhonghan Zhang
Zhonghan Zhang
JXJinhui Xue
Jinhui Xue
YYYunpeng Yang
Yunpeng Yang
WFWenfeng Fang
Wenfeng Fang
YHYan Huang
Yan Huang
HZHongyun Zhao
Hongyun Zhao
TP53 comutation is related to poor prognosis of non‐small cell lung cancer. However, there is limited study focusing on the structural influence of TP53 mutation on third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) treatment. We retrospectively analyzed the clinical and molecular data of patients treated with third‐generation EGFR‐TKIs in two independent cohorts. A total of 117 patients from the Sun Yat‐sen University Cancer Center (SYSUCC) and 141 patients from the American Association for Cancer Research Project GENIE database were included. In the SYSUCC cohort, TP53 comutations were found in 59 patients (50.4%) and were associated with poor median progress‐free survival (mPFS) and median overall survival (mOS). The additional subtype analysis found that TP53 mutation in the alpha‐helix region had shorter mOS compared with those with TP53 mutations in other regions in the SYSUCC cohort (mOS, 12.2 vs. 21.7 months; p = 0.027). Similar findings were confirmed in the GENIE cohort. Specifically, the presence of TP53 mutation in the alpha‐helix region was an independent negative predictive factor for PFS [hazard ratio (HR) 2.05(1.01–4.18), p = 0.048] and OS [HR 3.62(1.60–8.17), p = 0.002] in the SYSUCC cohort. TP53 mutation in alpha‐helix region was related to inferior clinical outcomes in patients treated with third‐generation EGFR‐TKIs.